Rubedo Life Sciences Reports Positive Phase 1 Results for First-in-Class GPX4 Modulator RLS-1496 in Dermatological Conditions
核心洞察
Rubedo Life Sciences (搜索) announced positive preliminary Phase 1 results for RLS-1496, the first-ever GPX4 (搜索) modulator tested in humans, showing good safety and tolerability with no serious adverse events in a 4-week study.
The drug demonstrated statistically significant clinical improvements in psoriasis and atopic dermatitis (搜索) patients, with 25% of atopic dermatitis subjects achieving ≥4-point reduction in itching scores and 20% reduction in epidermal thickness observed in psoriasis patients.
RLS-1496 showed dose-dependent target engagement and reduction of senescent cells associated with decreased inflammatory cytokines, representing a novel therapeutic approach targeting cellular aging mechanisms.
Rubedo Life Sciences (搜索) announced positive preliminary results from its Phase 1 clinical trial of RLS-1496, marking the first human study of a GPX4 (搜索) (selective glutathione peroxidase 4) modulator and the first drug specifically targeting cellular rejuvenation. The single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial evaluated patients with plaque psoriasis (搜索), atopic dermatitis (搜索), and photo-aged skin (搜索) in the European Union.
Safety Profile and Primary Endpoint Achievement
The 4-week study met its primary endpoint, with RLS-1496 demonstrating excellent safety and tolerability. No serious adverse events occurred, and no patients discontinued treatment due to adverse events or tolerability issues during the study period.
Clinical Efficacy Across Multiple Dermatological Conditions
Psoriasis Results
In psoriasis patients, RLS-1496 showed clear dose-response relationships across three concentrations (0.1%, 0.5%, and 1.0%). All doses were well-tolerated, leading the company to focus on the 1.0% concentration for future development. Key findings included:
- Dose-related target engagement of RLS-1496 and GPX4
- Overall reduction in senescent cells in mid- and high-dose cohorts
- Reduction of senescent cells associated with decreased inflammatory cytokines IL-19 and S100A7, not observed in vehicle-treated patients
- Average 20% reduction in epidermal thickness observed on histology after one month of treatment
- Statistically significant relationship between target engagement and clinical psoriasis severity improvement
Atopic Dermatitis Outcomes
Atopic dermatitis (搜索) patients demonstrated even more pronounced responses to RLS-1496 treatment. After one month, 25% of subjects treated with RLS-1496 achieved a ≥4-point improvement in pruritus (itching) on the numeric rating scale, while no vehicle-treated subjects reached this threshold. The drug showed higher levels of target engagement and substantial clinical improvement in this patient population.
Photo-Aging Effects
Early data from photo-aging assessments revealed dose-dependent target engagement in non-lesional photo-aged skin (搜索). Histology, proteomics, and spatial transcriptomics analyses indicated increased collagen gene and protein expression over time, particularly in dermal fibroblasts. Spatial transcriptomics also showed decreased senescence-associated secretory phenotype (SASP) and inflammatory biomarkers in keratinocytes with treatment.
Mechanism of Action and Drug Development
RLS-1496 represents a potential first-in-class, disease-modifying GPX4 (搜索) modulator that selectively targets pathologic senescent cells driving chronic degenerative diseases associated with biological aging. The drug works by modulating GPX4 in ferroptosis-sensitive senescent cells, sensitizing them to ferroptosis—a type of programmed cell death considered an Achilles heel of senescent cells.
Beyond its senolytic function, RLS-1496 may act as a restorative modulator, inducing a "redox-reset" in stressed neighboring cells to clear chronic inflammation sources while re-establishing healthy tissue homeostasis. The drug is being developed for both topical and oral administration using Rubedo's proprietary AI-driven ALEMBIC™ drug discovery platform.
Clinical Development Pipeline
A second Phase 1b/2a study evaluating RLS-1496 in actinic keratosis (搜索) (precancerous skin lesions) is currently underway in the United States, with completion expected later this year. Both trials include treatment of photo-aged skin (搜索) in addition to lesional skin, providing Rubedo with a comprehensive dataset on aging skin treatment from approximately 70 subjects.
"We're pleased by the positive safety and tolerability seen in the trial, with the additional preliminary results exceeding our expectations by showing very promising and clinically meaningful results across multiple measures including histologic, cellular, biomarker, and clinical evaluations in psoriasis, atopic dermatitis (搜索), and photo-aged skin (搜索)," said Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD. "It's uncommon to see clinical effect in a Phase 1 dermatology study given the shorter study duration and smaller sample size, and we are excited by the potential of this treatment with the clinical and biomarker changes we have observed already."
Scientific Significance and Future Presentations
Chief Scientific Officer and Founder Marco Quarta, PhD, emphasized the groundbreaking nature of the research: "This is one of the first comprehensively evaluated trials of a senotherapeutic drug that targets aging pathologic cells and regenerates healthy cells, and also the first human trial of a GPX4 (搜索) modulator. These preliminary results show the drug working mechanistically as expected and even better than should be expected clinically in a 4-week trial."
The company plans to present additional results at the Society for Investigative Dermatology meeting from May 13-16, 2026, in Chicago. Dr. Beddingfield will also moderate a panel on senescence and skin at the Dermatology Innovation Forum during the American Academy of Dermatology annual meeting on March 26 in Denver.